AI Analysis | Feedback

A discovery-stage Regeneron, but entirely dedicated to finding new immunotherapies for cancer.

A smaller, early-stage Merck, singularly focused on finding the next breakthrough cancer immunotherapy.

AI Analysis | Feedback

• NC410: An immunomedicine designed to block Siglec-15, aiming to restore anti-tumor immunity in various cancers.
• NC762: An immunomedicine designed to block B7-H4, aiming to enhance anti-tumor responses in multiple solid tumor types.

AI Analysis | Feedback

NextCure (NXTC) is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines. As such, it does not have "customers" in the traditional sense of selling a commercialized product directly to end-users or healthcare providers. Instead, its primary source of revenue comes from strategic collaboration and licensing agreements with other pharmaceutical companies.

Currently, NextCure's major customer, and its sole source of collaboration revenue, is:

• Eli Lilly and Company (Symbol: LLY)

NextCure entered into an exclusive worldwide license and collaboration agreement with Eli Lilly and Company in December 2020 for the development and commercialization of NC762, an antibody targeting B7-H4. Under this agreement, NextCure receives upfront payments, is eligible for potential development and commercial milestone payments, and tiered royalties on future product sales if NC762 is successfully commercialized.

AI Analysis | Feedback

AI Analysis | Feedback

Michael Richman President & CEO

Mr. Richman co-founded NextCure in 2015. He brings over 30 years of industry experience, including roles in research, project management, intellectual property, business development, and strategic planning. Prior to NextCure, he served as President and Chief Executive Officer of Amplimmune, which he founded in 2007 and was acquired by MedImmune/AstraZeneca in 2013. Mr. Richman also held positions as Executive Vice President and Chief Operating Officer of MacroGenics from 2002 to 2007, and Senior Vice President of Corporate Development and Administration at MedImmune from 2000 to 2002. From 1985 to 1996, he worked at Chiron (now Novartis) in various business development and intellectual property roles.

Steven P. Cobourn, CPA Chief Financial Officer

Mr. Cobourn possesses over 20 years of experience in life sciences, encompassing financing, product launches, alliances, and operations. Before joining NextCure, he was the Chief Financial Officer of Vaccinex, Inc., a private biotech where he supported its financing and facilitated IPO readiness. Previously, he was the Vice President of Finance and Treasurer of Otsuka America Pharmaceutical, Inc., during a period of significant growth and a blockbuster product launch. He also supported Otsuka's parent company during its 2010 IPO in Japan.

Timothy Mayer, Ph.D. Chief Operating Officer

Dr. Mayer has over 25 years of extensive experience in the biopharmaceutical industry, covering antibody therapeutics, small molecule pharmaceuticals, and molecular biology research tools. Before NextCure, he served in several roles at MacroGenics, where he managed intellectual property matters, assisted with business development for licensing transactions, and helped facilitate MacroGenics' initial public offering. He also worked at an intellectual property law firm, drafting and prosecuting biotech and pharmaceutical applications, and developed cloning systems at Life Technologies and Invitrogen.

Sol Langermann, Ph.D. Chief Scientific Officer

Dr. Langermann most recently served as Senior Vice President and Chief Scientific Officer (CSO) of Amplimmune (now MedImmune/AstraZeneca), an acquisition by AstraZeneca. He played a critical role in developing Amplimmune, which led to multiple Investigational New Drug (IND) applications, successful partnering activities with GlaxoSmithKline and Daiichi Sankyo, and the company's acquisition. Prior to Amplimmune, Dr. Langermann held several positions at MedImmune, including Senior Director of Cell Biology and Director of Immunology and Molecular Genetics. He also headed Research and Development efforts and served as CSO at PharmAthene (now Altimmune).

Udayan Guha, M.D., Ph.D. Chief Medical Officer

Dr. Guha is a physician-scientist with more than 15 years of clinical development experience across academia, pharmaceutical, and biotech sectors, focusing on targeted therapy, immunotherapy, and cellular therapy. Before joining NextCure, he was the Vice President, Head of Clinical Development at TCR2 Therapeutics, which is now part of Adaptimmune. Prior to TCR2 Therapeutics, Dr. Guha held Senior Director and Director positions in Early Clinical Development at Bristol Myers Squibb, where he was the Clinical Lead for several first-in-class, first-in-human immunotherapy studies. He also had a productive academic career as an Investigator at the National Cancer Institute (NCI), National Institutes of Health (NIH).

AI Analysis | Feedback

The key risks to NextCure (NXTC) are primarily associated with its status as a clinical-stage biopharmaceutical company with no commercialized products.

1. Limited Operating History, Significant Losses, and Need for Additional Financing: NextCure has a limited operating history and has not yet brought any products to market, nor has it generated revenue from product sales. The company consistently reports significant losses and anticipates these losses will continue for the foreseeable future, making profitability uncertain. This financial profile necessitates ongoing efforts to secure additional funding, which carries inherent risks regarding the availability and terms of such financing. Despite a recent private placement extending its cash runway into the first half of 2027, the company's high cash burn rate remains a concern.
2. Clinical Development and Regulatory Approval Risks: As a biotechnology company, NextCure's success is heavily dependent on the successful outcome of its clinical trials, followed by regulatory approval and eventual commercialization of its product candidates. There is a significant risk that positive results observed in preclinical studies or early-stage clinical trials may not be replicated or predictive of success in later, larger clinical trials. The company has previously faced challenges, including disappointing study results that led to the abandonment of a former lead therapy.
3. Dependence on Key Personnel: NextCure's operations and strategic execution rely significantly on its key management and scientific personnel. The loss of such individuals could adversely affect the company's ability to discover, develop, and advance its product pipeline.

AI Analysis | Feedback

AI Analysis | Feedback

NextCure (NXTC) is a clinical-stage biopharmaceutical company focused on developing immunomedicines to treat cancer and other immune-related diseases. The addressable markets for their main product candidates are detailed below:

NC410 (LAIR-2 fusion protein)

NC410 is being evaluated in combination with pembrolizumab for the treatment of ovarian cancer and immune checkpoint inhibitor (ICI) naive and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC).

• Ovarian Cancer Market: The global ovarian cancer market size was valued at USD 1.35 billion in 2024 and is anticipated to reach USD 31.64 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 23.8% from 2025 to 2033. Other estimates place the global ovarian cancer market at USD 2.3 billion in 2024, projected to reach USD 5.5 billion by 2033 (CAGR of 9.59% from 2025-2033), and USD 3.06 billion in 2023, expected to reach USD 31.31 billion by 2034 (CAGR of 23.53% from 2024-2034). The global ovarian cancer drugs market was estimated at USD 3.37 billion in 2022 and is anticipated to reach USD 5.65 billion by 2030, growing at a CAGR of 6.6% from 2023 to 2030.
• Colorectal Cancer Market (MSS/MSI-L): The global colorectal cancer therapeutics market is expected to reach USD 30,095.9 million by 2033, from USD 22,275.3 million in 2024, at a CAGR of 3.4% from 2024 to 2033. Microsatellite Stable (MSS) Colorectal Cancer represents the majority of colorectal cancer cases. The metastatic colorectal cancer (mCRC) market was valued at US$ 5,662.9 million in 2023 and is forecasted to expand at a CAGR of 5.1% to reach US$ 9,787.5 million by 2034. Approximately 5% to 15% of colorectal cancers exhibit deficiencies in the mismatch repair (dMMR) system and high microsatellite instability (MSI-H).

LNCB74 (B7-H4 Antibody-Drug Conjugate - ADC)

LNCB74 targets B7-H4 expressing solid tumors, including breast, ovarian, and endometrial cancers, as well as subsets of other cancer types like lung and biliary tract cancer.

• B7-H4 Targeting Therapies Market (7MM - US, Germany, France, Italy, Spain, UK, Japan): The total market size for B7-H4 targeting therapies in the 7MM is expected to surge significantly by 2040.
• Antibody Drug Conjugates (ADCs) Market (Global): The global antibody drug conjugates market size was estimated at USD 11.29 billion in 2023 and is expected to reach USD 24.01 billion by 2030, growing at a CAGR of 9.2% from 2024 to 2030. North America accounted for the largest revenue share of 52.54% in 2023. Other projections estimate the global ADC market to reach USD 51.2 billion by 2033 (CAGR of 15.8%), or around USD 31.96 billion by 2034 (CAGR of 10.83% from 2025-2034). The U.S. ADC market is projected to be USD 4.9 billion in 2024, reaching USD 17.1 billion in 2033.

NC525 (LAIR-1 monoclonal antibody - mAb)

NC525 is in a Phase 1a dose escalation study for relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome, and chronic myelomonocytic leukemia.

• Acute Myeloid Leukemia (AML) Treatment Market: The global acute myeloid leukemia treatment market size was estimated at USD 3.47 billion in 2024 and is projected to reach USD 6.29 billion by 2030, growing at a CAGR of 10.6% from 2025 to 2030. North America accounted for 37.6% of the global market in 2024, with the U.S. representing 90.9% of the North American market. Other estimates for the global AML market include USD 2.3 billion in 2022 (across 8MM), USD 2.88 billion in 2025, reaching USD 4.72 billion by 2030, and USD 2.1 billion in 2023, growing at a CAGR of 10.7% from 2024 to 2032.
• Myelodysplastic Syndrome (MDS) Drugs Market: The global myelodysplastic syndrome drugs market size was estimated at USD 2.88 billion in 2023 and is projected to reach USD 5.28 billion by 2030, growing at a CAGR of 9.1% from 2024 to 2030. The global MDS treatment market size is estimated to be valued at US$ 3,265.6 million in 2022 and is expected to reach US$ 6,635.3 million in 2030, exhibiting a CAGR of 9.3%. The market size across the top 7 markets (US, EU4, UK, Japan) for MDS was USD 2.4 billion in 2024, expected to reach USD 4.8 billion by 2035 (CAGR of 6.29%). North America holds the largest market share, accounting for 40% of the global MDS treatment market.
• Chronic Myelomonocytic Leukemia (CMML) Market: The chronic myelomonocytic leukemia market is estimated to be valued at USD 1012.9 million in 2025 and is expected to reach USD 1584.4 million by 2032, growing at a CAGR of 6.6% from 2025 to 2032. The global CMML market is valued at approximately $2.1 billion as of 2024 and is expected to reach around $4.5 billion by 2034, growing at a CAGR of 8.1% from 2025 to 2034. North America currently dominates the market, contributing over 45% of the total revenue.

AI Analysis | Feedback

1. Advancement of LNCB74 (B7-H4 ADC) through clinical development: LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4 for multiple cancers, is a primary focus for NextCure. The company completed cohort 1 of its Phase 1 trial in February 2025 and plans to initiate additional backfill cohorts in the second half of 2025. Proof of concept data readouts for LNCB74 are anticipated in the first half of 2026. Positive clinical trial results and progression towards later-stage development or potential regulatory approvals would be crucial for future revenue generation.
2. Progress of SIM0505 (CDH6 ADC) in clinical trials and global expansion: NextCure acquired global rights (excluding Greater China) for SIM0505, another novel ADC targeting CDH6, in June 2025. The first U.S. patient was dosed in October 2025 in an ongoing Phase 1 trial. Proof of concept data readouts for SIM0505, including data from an ongoing Phase 1 trial in China by partner Simcere Zaiming, are expected in the first half of 2026. Successful clinical development and potential commercialization of SIM0505 represent a significant revenue driver.
3. Strategic partnerships and milestone payments for pipeline candidates: As a clinical-stage company without product sales, NextCure relies on public offerings, partnerships, and milestone payments. The company is actively seeking strategic partners for its preclinical non-oncology programs, such as NC181 (targeting Alzheimer's disease) and NC605 (for osteogenesis imperfecta). Securing such partnerships could provide upfront payments and future milestone payments as these programs advance, contributing to revenue.

AI Analysis | Feedback

Share Issuance

• NextCure executed a 1-for-12 reverse stock split on July 14, 2025.
• The number of shares outstanding increased by 0.78% in one year prior to October 28, 2025.

Inbound Investments

• Simcere Zaiming, a US affiliate, made a $2.0 million equity investment in NextCure in June 2025.

Outbound Investments

• NextCure acquired global rights to SIM0505 (CDH6 ADC) in June 2025, excluding Greater China.
• This acquisition included a $12.0 million upfront license fee paid to Simcere Zaiming.

Capital Expenditures

• NextCure's capital expenditures for the last 12 months (prior to October 28, 2025) were approximately $136,000.
• As of November 2025, NextCure expects its current financial resources to be sufficient to fund operating expenses and capital expenditures into mid-2026.
• Previously, as of March 2025, the company expected to fund operating expenses and capital expenditures into the second half of 2026.